![]() |
Syneos Health Releases Report Identifying Barriers to Payer Use of RWE in Rare Disease and Recommendations for Advancing Payer Engagement | ![]() |
Thursday, 21. November 2019 15:02 |
---|
MORRISVILLE, N.C. and NEW YORK , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released “Real World Value: Advancing Payer Understanding of RWE in Rare Disease,” a report identifying payer barriers to use of Real World Evidence (RWE) and opportunities to advance understanding and engagement. The report includes firsthand feedback – generated from the Syneos Health Payer Panel comprised of more than 300 payers in the U.S. and Europe – exploring the acceptability of RWE on payer decisions for rare therapies and perspectives on how their stance is likely to evolve over time. Drug developers and global regulators are rapidly expanding RWE use to design, test and review rare disease treatments, unlocking the potential to speed innovative treatments to market. When used in tandem with other pricing and reimbursement innovations, RWE can contribute to a multi-dimensional value picture. However, payer perception surrounding RWE benefits for rare disease therapies lags behind the industry and regulators as payers may not be as receptive to or as familiar with RWE-based presentations. “Our research reveals that payers are positively disposed to use RWE, but knowledge gaps around the validity and value of RWE must be closed to improve access for rare disease patients,” said Alistair Macdonald, Chief Executive Officer, Syneos Health. “Multi-stakeholder feedback points to the need for collaborative, well-structured exercises and standard-setting for payers to advance at the same velocity as other industry stakeholders. Dialogue is key, and the time to facilitate these conversations is now.” Key Syneos Health Payer Panel survey findings include: Language Barrier Indicates Need for Standard RWE Lexicon:
Perception of RWE Benefits Varies Among Payers Worldwide:
RWE Data Submission Limitations:
Reputable Sources for Decision Making Point to Need to Leverage KOLs Whom Payers Trust:
“While payer engagement surrounding RWE in the rare disease space differs from industry and regulators, our research uncovers no trend or obstacles to advancing their understanding as long as regulatory bodies and industry groups are attentive to their concerns,” said Macdonald. “Our Insights Hub allows us to share these insights broadly across industry stakeholders to accelerate innovation and speed market access to change patients’ lives.” Download the full report, including qualitative feedback and recommendations for accelerating payer understanding. Contact our cross-functional Value and Access team who can help biopharmaceutical companies close evidentiary gaps across all therapeutic areas, including tapping into our robust Payer Panel. Syneos Health Insights Hub – New Destination Provides Real Answers to Guide Biopharma Decision Making and Investment About Syneos Health About the “Real World Value: Advancing Payer Understanding of RWE in Rare Disease” Survey Syneos Health Investor Relations Contact: Syneos Health Press/Media Contact: |
Related Links: |
Author: Copyright GlobeNewswire, Inc. 2016. All rights reserved. You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account. |